The increasing prevalence of allergy is a major health issue. Often appearing as atopic dermatitis in early childhood, allergies can progress to allergic rhinoconjunctivitis and severe allergic asthma.
This process has been termed the “atopic march” and new treatments are badly needed to control the debilitating symptoms and intervene in disease progression.
Timapiprant is a new class of drug that specifically inhibits a branch of the immune system - dependent on Th2 lymphocytes - known to be important in allergic responses. The importance of the Th2 pathway in the pathogenesis of eosinophilic asthma has been highlighted by approval of the anti-IL5 antibody mepolizumab.
However, though effective, as with all antibody-based treatments they are expensive and present compliance issues as they need to be delivered by injection.
There is, therefore, a continuing and significant need for a safe and effective oral therapy for eosinophilic asthma and associated conditions.